ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0301

Novel HMGCS1 Deficiency Expands Proinflammatory Monocytes and Cytotoxic Populations with Increased Cytokine Release

Sabrina Helmold Hait1, Mary Maclean2, Cindy Phung3, Gustaf wigerblad4, Iago Pinal Fernandez4, Carl Esperanzate5, hongying Wang5, Andrew Mammen6, willian Gahl5, Daniel L. Kastner7, Stefania Dell'orso4, Danica Novacic5, massimo Gadina4 and Ivona Aksentijevich8, 1NIAMS/NIH, Bethesda, MD, 2NIH-NIAMS, Rockville, MD, 3National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS), Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 5National Human Genome research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, MD, 6NIH, Bethesda, MD, 7National Human Genome research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, 8100, Bethesda, MD

Meeting: ACR Convergence 2025

Keywords: immunology, Inflammasome, interferon, Interleukins, Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0280–0305) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The mevalonate (MVK) pathway synthesizes isoprenoids that mediate post-translational protein modifications via prenylation. Deficient protein prenylation due to decreased mevalonate kinase (MK) activity leads to innate immune activation and autoinflammatory disorders. Patients using statins, HMG-CoA reductase inhibitors, may present with myopathy. However, the precise pathogenesis of prenylation deficiency-associated inflammation and myotoxicity remains unclear. We identified a rare homozygous pathogenic variant in the HMGCS1 gene (c.265C >T, p. Arg89Trp), encoding for HMG-CoA synthase, the first enzyme in the MVK pathway, in two siblings presenting with necrotizing myopathy, arthropathy/arthritis, and susceptibility to infections.

Methods: Single-cell RNA sequencing (scRNA-seq) was conducted on PBMCs obtained from affected siblings, an unaffected sibling (wild-type), the mother (heterozygous) and unrelated healthy control. Muscle biopsies from affected siblings were used for bulk RNA sequencing. Using spectral flow cytometry, whole blood and/or PBMCs from affected individuals were assessed for IFN-g, IL-1b and IL-6 expression in monocytes, while IFN-g, granzyme B and perforin were assessed on NK and T cells.

Results: ScRNA-seq data evidenced an expansion of activated monocyte and cytotoxic populations in the affected but not in the unaffected brother, suggesting monocytes, T and NK cells as drivers of inflammation. Since muscle biopsies of the affected brothers revealed a strong IFN-g signature and IL-1 and IL-6 are crucial for inflammasome formation, we investigated these cytokines and inflammatory markers in LPS-stimulated myeloid subsets, and IL-12-stimulated NK cells and T cells of affected and unaffected controls. Percentage of IL-1b+ and IL-6+ non-classical monocytes (NCM) were significantly elevated in the affected siblings. IFN-g levels were increased in all monocyte subpopulations of the affected siblings, consistent with the IFN-g signature observed in the muscle biopsies. Monocytes expressing inflammatory markers, such as CD64, Siglec-1, and CD11c, were increased with a marked expression in NCM. Classical monocytes (CM), intermediate monocytes (IM), and NCM of the affected siblings presented lower PSGL-1 levels, aligned with the observed inflammatory responses, suggesting an infiltration of activated monocytes into muscle tissues. We observed a decrease in NK cells in affected donors, while T cells, specifically Th1 and Th17 cells, were expanded. Further, T cells presented elevated IFN-g expression in affected siblings, correlating with T cells infiltration seen in muscle tissue. Notably, T cells of the affected donors showed higher expression of granzyme B and perforin but decreased CD107a, indicating these cells were activated but with diminished degranulation activity.

Conclusion: Our data provide strong evidence that monocytes and T cells may play a pivotal role in the pathogenesis of inflammation and necrotizing myositis in patients with HMGCS1 deficiency, with NCM and cytotoxic T cells presenting the most proinflammatory profile suggesting an important role of these cells in sustaining HMGCS1 mutation-associated autoinflammatory disorder.

Supporting image 1IFN-g, IL-1 and IL-6 release is increased in non-classical monocytes of HMGCS1 homozygous siblings.


Disclosures: S. Helmold Hait: None; M. Maclean: None; C. Phung: None; G. wigerblad: None; I. Pinal Fernandez: None; C. Esperanzate: None; h. Wang: None; A. Mammen: None; w. Gahl: None; D. Kastner: None; S. Dell'orso: None; D. Novacic: None; m. Gadina: None; I. Aksentijevich: In Vitro Diagnostics, 9.

To cite this abstract in AMA style:

Helmold Hait S, Maclean M, Phung C, wigerblad G, Pinal Fernandez I, Esperanzate C, Wang h, Mammen A, Gahl w, Kastner D, Dell'orso S, Novacic D, Gadina m, Aksentijevich I. Novel HMGCS1 Deficiency Expands Proinflammatory Monocytes and Cytotoxic Populations with Increased Cytokine Release [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/novel-hmgcs1-deficiency-expands-proinflammatory-monocytes-and-cytotoxic-populations-with-increased-cytokine-release/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-hmgcs1-deficiency-expands-proinflammatory-monocytes-and-cytotoxic-populations-with-increased-cytokine-release/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology